Study EvAluating Genotypes While Using Lucentis 2

Completed · Phase 4

Conditions studied: Age-Related Macular Degeneration

In brief

The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms

Key facts

Study ID

NCT01464723

Run by

University of California, San Diego

People needed

66

Starts

2008-05-01

Expected to finish

2013-01-01

Last updated by the study team

2019-08-14

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide written informed consent and comply with the study assessments for the full duration of the study.
• Age > 50 years.
• Treatment naïve (study eye only) AMD patients that are determined to be candidates for ranbizumab.
• Visual acuity 20/32 to 20/230.

You may not qualify if…

• Pregnancy
• Prior enrollment in the study
• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
• Previous therapy in study eye for AMD or other retinal disease which may be used in the treatment of AMD.
• Any other condition that the investigator believes would pose a significant hazard to the subject if on-label ranibizumab were prescribed
• Any participation in another simultaneous medical investigation or trial for AMD *Concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy, advanced glaucoma)

Where it is running

• Shiley Eye Center, University of California, San Diego — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.